Location Directory

Clinical trials in San Francisco, California

This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5145

Shown on this page

Current sort

Institutions in San Francisco

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UCSF

Live official records

Open in full search

Conditions: Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions: Ketamine infusion; Drug
Lead sponsor: Amanda Downey, MD; Other
Eligibility: 16 Years to 26 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: PSC
Interventions: Not listed
Lead sponsor: PSC Partners Seeking a Cure; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Uterine Cancer, Endometrial Cancer
Interventions: Zanzalintinib, Paclitaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 4
States / cities: San Francisco, California • St Louis, Missouri • Albuquerque, New Mexico + 1 more

Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions: XmAb541; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: HIV, STIs, STIs Prevention, HIV Prevention
Interventions: Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
Interventions: Spirometer, Oximeter, Scale, ePROs (electronic patient reported outcomes); Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more

Conditions: Erythropoietic Protoporphyria
Interventions: DISC-1459; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Minutes and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 278
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more

Conditions: Advanced Solid Tumor
Interventions: BNT326, Pumitamig, Itraconazole, Paroxetine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Castration-Resistant Prostatic Cancer, Metastasis
Interventions: Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Clinical trials in San Francisco, California

Filter and sort this location

Institutions in San Francisco

Live official records

Ketamine Effects on Learning In Eating Disorders

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Combatting HIV Or Other STIs Early (CHOOSE)

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)